Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2012

View Archived Issues

Astrocyte-based therapy proven effective in Alzheimer's disease model

Daiichi Sankyo patents new tyrosine-protein kinase inhibitors

Janssen Pharmaceutica divulges new MMP inhibitors

Spanish researchers disclose new GSK-3 beta inhibitors

Soligenix regains North American and European rights to oral BDP

Data presented from a randomized trial comparing rehydration methods in children

BP-2-047 shows antitumor activity against STAT3-activated myeloma in vitro

Baxter presents clinical results for its rFIX protein as hemophilia B treatment

Targeted methods of protein gene therapy for the treatment of brain injury

Janus Biotherapeutics presents novel TLR9 antagonists

Xoma Corp. patents new monoclonal antibodies

Scientists at Lacer divulge novel agents for pain

Novel protein kinase inhibitors prepared at Bayer Intellectual Property

New conjugate presented for metabolic syndrome

Omeros reports results from pivotal phase III trial of OMS-103HP in surgical patients

Johns Hopkins receives additional NIH grant for studies of Q-Cells in ALS

Biotie's nepicastat fails to show efficacy in relieving PTSD symptoms

SBI Holdings reorganizes consolidated subsidiaries to improve efficiency

Japanese group enters agreement for new anticancer compounds

CytImmune and AstraZeneca to study new cancer nanomedicine

FDA accepts supplemental BLA filing for Xiaflex

Kissei submits application in Japan for combination therapy including Glufast

FDA approves Eliquis

Significant reduction in plasma antithrombin demonstrated in nonhuman primates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...